Please assess the completion status of the following clinical trial:

Trial Title: Cost Comparison Study of Darbepoetin Versus Epoetin Therapy to Treat Anemia in Hemodialysis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age ≥19 years~* receiving in-center hemodialysis two or more times weekly~* anemia requiring erythropoiesis stimulating (ESA) agent therapy OR a hemoglobin(Hb)\<100g/L in the absence of other causes of anemia~* if female, must be using an approved method of contraception or judged unable to become pregnant~* able to give informed consent~Exclusion Criteria:~* acute kidney injury likely to resolve~* plans to change to peritoneal dialysis or home hemodialysis, or planned transplant from a living donor~* expected lifespan of less than six months due to a medical condition other than chronic kidney disease~* current hematologic condition that may cause anemia~* use of medications known to cause anemia~* use of any investigational drug or androgen within 90 days of screening~* significant bleeding within 30 days of screening~* red blood cell transfusion(s) within 30 days of screening~* documented or suspected pure red cell aplasia (PRCA)~* current iron deficiency~* documented allergy or intolerance to intravenous sodium ferric gluconate~* known or probable ESA resistance~* uncontrolled hypertension~* an intention to relocate to a different dialysis center in the near future

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Epoetin alfa (Type: ACTIVE_COMPARATOR): Patients who are enrolled and randomized to the Epoetin arm will remain on their current dose and frequency. After the first hemoglobin (Hb) measurement the study algorithm will be used to guide anemia management. The subjects in this arm will remain on epoetin for the required run-in phase followed by the 12 month active phase.
- Darbepoetin alfa (Type: ACTIVE_COMPARATOR): Patients who are enrolled and randomized to the Darbepoetin arm will have their epoetin discontinued at the end of the week preceding entry into the study and will switch to darbepoetin on the date that they would normally be receiving their next dose of epoetin.~Switching patients to darbepoetin will be done using the conversion ratio of 200 units of epoetin to 1 μg of darbepoetin as used per week, rounded up or down to the nearest available pre-filled syringe dose available from the manufacturer.~After the first Hb measurement the study algorithm will be used to guide anemia management. The subjects in this arm will remain on darbepoetin for the required run-in phase followed by the 12 month active phase.

Based on this trial design, predict the completion outcome and termination type (if applicable).